Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Reduce” from Brokerages

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned an average recommendation of “Reduce” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company.

Several equities research analysts recently commented on the stock. Sanford C. Bernstein reissued a “market perform” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, March 7th. Wolfe Research cut shares of Bayer Aktiengesellschaft from an “outperform” rating to a “peer perform” rating in a report on Tuesday, January 30th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, February 29th.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY opened at $7.04 on Friday. The firm’s 50-day moving average price is $7.44 and its 200-day moving average price is $8.90. The company has a quick ratio of 0.80, a current ratio of 1.27 and a debt-to-equity ratio of 1.15. Bayer Aktiengesellschaft has a 1-year low of $6.96 and a 1-year high of $16.84.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, March 5th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.38 by $0.12. Bayer Aktiengesellschaft had a negative net margin of 6.31% and a positive return on equity of 17.27%. The business had revenue of $12.77 billion for the quarter. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.36 earnings per share for the current year.

Bayer Aktiengesellschaft Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Monday, May 13th. Stockholders of record on Tuesday, April 30th will be issued a dividend of $0.0191 per share. The ex-dividend date is Monday, April 29th. Bayer Aktiengesellschaft’s payout ratio is -54.88%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.